VȚ

Victoria Țău

Clinica de Pneumologie Iaşi

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Antigona Trofor

Clinica de Pneumologie Iaşi

Radu Crișan-Dabija

Grigore T. Popa University of Medicine and Pharmacy

Paula Vasilache Antohi

Clinica de Pneumologie Iaşi

Ioana Stoian

Clinica de Pneumologie Iaşi

A Antal

Clinica de Pneumologie Iaşi

Andreea Zabara-Antal

Clinica de Pneumologie Iaşi

Adriana-Loredana Pintilie

Clinica de Pneumologie Iaşi

Adriana Loredana Pintilie

Clinica de Pneumologie Iaşi

Adelina Stoian

Grigore T. Popa University of Medicine and Pharmacy

Paula Vasilache-Antohi

Cooperative Institutions

Clinica de Pneumologie Iaşi

Grigore T. Popa University of Medicine and Pharmacy

Spitalul Clinic C.F. Iasi

University of Waterloo

Collegium Civitas

Romanian Waters National Administration

European Network for Smoking and Tobacco Prevention

Constanta Maritime University

Spitalul Clinic de Recuperare

Institut des Sciences et Technologies Moléculaires d'Angers

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Exploring the ESKAPE maze: Pneumonias, resistance and therapeutic perspectives

Pneumologia (2023)

Ioana Stoian A Antal Paula Vasilache Antohi Victoria Țău Adriana Loredana Pintilie

Abstract The article explores drug-resistant bacteria within the ESKAPE group, commonly associated with nosocomial infections, focusing on the resistance mechanisms of Acinetobacter baumannii and Klebsiella pneumoniae. The study delves into various β-lactamase enzymes and resistance mechanisms exhibited by ESKAPE bacteria, shedding light on the challenges posed by carbapenem-resistant infections. Notably, the article underscores the ongoing need for research to develop more effective treatments and address the persistent challenges associated with drug resistance in the context of nosocomial infections. The examination of this subset of bacteria aims to contribute to a comprehensive understanding of their resistance mechanisms and provides insights into the difficulties encountered in treating infections with carbapenem-resistant pathogens. The article serves as a valuable resource for clinicians, researchers and policymakers, offering a detailed perspective on the current state of drug resistance among nosocomial pathogens and advocating for continuous research to enhance treatment efficacy in the face of evolving challenges.

10.2478/pneum-2024-0020

Cite

Citations (0)

Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis

Pneumologia (2023)

Victoria Țău A Antal Paula Vasilache Antohi Ioana Stoian Adriana Loredana Pintilie

Abstract The pandemic of the coronavirus disease 2019 (COVID-19) has affected millions of people worldwide. Patients can develop a lot of different manifestations, from asymptomatic form to severe acute respiratory distress syndrome (ARDS). Pulmonary fibrosis, as a primary cause of mortality, is the main consequence of lung injury caused by acute respiratory distress syndrome. Unfortunately, effective treatment for pulmonary fibrosis has not yet been found; that’s why we found an essential anti-fibrotic agent in the early acute phase of severe COVID-19 to fight the infection outcomes. This narrative review presents the therapeutic strategy and the importance of fighting pulmonary fibrosis to help patients worldwide protect themselves against severe and fatal viral infections. To prevent long-term sequelae and early mortality, it’s necessary to test the efficacy of anti-inflammatory drugs.

Nintedanib

2019-20 coronavirus outbreak

10.2478/pneum-2024-0014

Cite

Citations (0)

The interconnection between Obesity and Asthma-Obstructive Sleep Apnea Overlap: A Comprehensive Review

Pneumologia (2023)

Paula Vasilache Antohi Andreea Zabara-Antal Ioana Stoian Adriana-Loredana Pintilie Victoria Țău

Abstract Asthma and sleep-related respiratory disorders represent common and well-characterized respiratory pathologies, yet ongoing debates persist regarding their association and potential bidirectional relationship. We performed a literature search encompassed PubMed and MEDLINE, exploring studies and publications on the overlap of sleep apnea and asthma, especially considering their common risk factor, obesity. Observational studies, including prospective and retrospective cohort studies, meta-analyses, and case reports, were analyzed. The available data indicate a bidirectional relationship between asthma and obstructive sleep apnea (OSA), with each condition influencing the other. Asthma is identified as a risk factor for OSA, exacerbating its severity, while OSA has been linked to the development and progression of asthma. Results Obesity plays a critical role as an independent risk factor connecting asthma to OSA, emphasizing the intricate interplay between these conditions. A body mass index (BMI) ≥ 25 kg/m2 is a central risk factor for OSA. Conclusion This research underscores the need for further exploration into the nuanced mechanisms linking obesity, obstructive sleep apnea, and asthma. Additionally, innovative interventions and treatment modalities tailored to address these interconnected health issues are imperative for personalized and targeted approaches in managing patients with obesity-related complications, ultimately improving overall health outcomes.

Sleep

10.2478/pneum-2024-0018

Cite

Citations (0)

Systemic inflammation and obstructive sleep apnea syndrome (OSA): the role of C–reactive protein (CRP)

Pneumologia (2023)

Adriana-Loredana Pintilie Andreea Zabara-Antal Paula Vasilache-Antohi Victoria Țău Adelina Stoian

Abstract The presence of sleep-related disorders, particularly obstructive sleep apnea syndrome (OSA), instigates pathological changes during sleep, giving rise to frequent hypoxic episodes that generate elevated levels of a broad spectrum of inflammatory cytokines. C-reactive protein (CRP), a biomarker signifying the presence and intensity of inflammation, is frequently detected in elevated serum or plasma concentrations, correlating with the number of respiratory events, especially in moderate and severe forms, across both adults and children. Various available therapeutic approaches demonstrate the capacity to diminish serum levels, although the minimum duration of usage typically extends between 2-6 months. In the case of older individuals, OSA commonly coexists with additional conditions, further augmenting the baseline inflammatory level. This accelerated disease progression amplifies mortality rates, incurs heightened costs, and significantly diminishes the overall quality of life.

Sleep

10.2478/pneum-2024-0002

Cite

Citations (0)